Research location
Greenlawn
New York, United States
Advertisement
Research activity in Greenlawn
New York, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 14 trials and 14 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Greenlawn
14 linked trials · page 1 of 1ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation
RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 1 site observation
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation
RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast CancerNCT05705401 · 2023-05-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerNCT03633331 · 2018-08-15 · 1 site observation
COMPLETED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.